Logo

Corvus Pharmaceuticals, Inc.

CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK… read more

Healthcare

Biotechnology

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$13.26

Price

+0.53%

$0.07

Market Cap

$1.115b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$44.168m

+75.8%

1y CAGR

-6.7%

3y CAGR

-3.9%

5y CAGR
EPS

-$0.55

+48.0%

1y CAGR

+1.0%

3y CAGR

+4.1%

5y CAGR
Book Value

$240.679m

$253.195m

Assets

$12.516m

Liabilities

$834k

Debt
Debt to Assets

0.3%

-

Debt to EBITDA
Free Cash Flow

-$35.137m

-26.7%

1y CAGR

-6.9%

3y CAGR

+1.3%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases